Galectin-3 predicts cardiovascular events in patients with type-2 diabetes
Session title: Coronary Artery Disease (Chronic) ePosters
Topic: Coronary Artery Disease and Comorbidities
Session type: ePosters
Available from:

View abstract

A Lorenzo-Almoros1 , A Pello2 , A Acena2 , J Martinez-Milla2 , N Tarin3 , C Cristobal4 , LM Blanco-Colio5 , JL Martin-Ventura5 , A Huelmos6 , C Gutierrez-Landaluce4 , M Lopez-Castillo2 , J Alonso7 , J Egido8 , O Lorenzo5 , J Tunon2 , 1Fundacion Jimenez Diaz University Hospital, Internal Medicine - Madrid - Spain , 2Fundacion Jimenez Diaz University Hospital, Cardiology - Madrid - Spain , 3Hospital de Mostoles - Madrid - Spain , 4Hospital de Fuenlabrada, Cardiology - Madrid - Spain , 5Fundacion Jimenez Diaz University Hospital, Laboratory of Vascular Pathology, IIS - Madrid - Spain , 6Hospital de Alcorcon, Cardiology - madrid - Spain , 7Hospital de Getafe, Cardiology - madrid - Spain , 8Fundacion Jimenez Diaz University Hospital - Madrid - Spain ,


Citation: N/A

Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population.

We followed 964 patients with coronary artery disease (CAD), assessing at baseline galectin-3, monocyte chemoattractant protein-1 (MCP-1) and N-terminal fragment of brain natriuretic peptide (NT-proBNP) plasma levels. Secondary outcomes were acute ischemia and heart failure or death. Primary outcome was the combination of the secondary outcomes.

Male patients were 75.0% in T2DM and 76.6% in the non-T2DM subgroup, (p=0.609). Age was 61.0 (54-72) and 60.0 (51-71) years, respectively (p=0.092). 232 patients had T2DM. Patients with T2DM showed higher MCP-1 [144 (113-195) vs. 133 (105-173) pg/ml, p=0.006] and galectin-3 [8.3 (6.5-10.5) vs. 7.8 (5.9-9.8) ng/ml, p=0.049] levels.

Median follow-up was 5.39 years (2.81- 6.92). Galectin-3 levels were associated with increased risk of the primary outcome in T2DM patients [HR 1.57 (1.07-2.30);p=0.022], along with a history of cerebrovascular events. Treatment with clopidogrel was associated with lower risk. In contrast, NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in non-diabetic patients [HR 1.21 (1.04-1.42);p=0.017 and HR 1.23 (1.05-1.44); p=0.012, respectively], along with male sex and age.

Galectin-3 was also the only biomarker that predicted the development of acute ischemic events and heart failure or death in T2DM patients, while in non-diabetics MCP-1 and NT-proBNP, respectively, predicted these events.

In CAD patients, cardiovascular events are predicted by galectin-3 plasma levels in patients with T2DM, and by MCP-1 and NT-proBNP in those without T2DM.